Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 11, 2013, Pages

  Lee, Tim W R ^a   Southern, Kevin W ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; PLACEBO;

ADVERSE EVENT; CLINICAL OUTCOME; CYSTIC FIBROSIS; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE TRANSFER; HUMAN; LIFE EXPECTANCY; LUNG DISEASE; LUNG FUNCTION TEST; LUNG INFECTION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FUNCTION; REVIEW; SYSTEMATIC REVIEW; X-RAY COMPUTED TOMOGRAPHY; GENE THERAPY; GENETICS; META ANALYSIS; METHODOLOGY; TARGETED GENE REPAIR;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; TARGETED GENE REPAIR;

EID: 84900788535     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005599.pub4     Document Type: Review

References (60)

1. Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. The Lancet 1999;353(9157):947-54. [CFGD Register: BD11a]
2. Davies MG, Stern M, Geddes DM, Alton EWFW. Reduction in sputum inflammatory cells and IL-8 following pulmonary administration of liposome mediated CFTR gene transfer in CF subjects [abstract]. Thorax 1998;53(Suppl 4):A14. [CFGD Register: BD11b]
3. Stern M, Phillips J, Jaffe A, Farley R, Chadwick S, Davies J. A double blind placebo controlled trial of pulmonary and nasal administration of liposome-mediated CFTR gene transfer in CF subjects [abstract]. American Journal of Respiratory and Critical Care Medicine 1998;157(3 Suppl):A564. [CFGD Register: BD11d]
4. Stern M, Phillips J, Jaffe A, Farley R, Chadwick S, Davies J, et al. A double blind placebo controlled trial of pulmonary and nasal administration of liposome-mediated CFTR gene transfer in CF subjects [abstract]. Thorax 1997;52(Suppl 6):A3. [CFGD Register: BD11c]
5. Moss RB, Aitken M, Clancy J, Milla C, Rodman D, Spencer T, et al. A multicenter, double-blind, placebo controlled, phase II study of aerosolized TGAAVCF in cystic fibrosis patients with mild lung disease [abstract]. Pediatric Pulmonology 2002;34(Suppl 24):250-1. [CFGD Register: BD17a]
6. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125(2):509-21. [CFGD Register: BD17b]
7. Moss RB, Heald AE, 25E01 SG. Phase 2B Trial of Aerosolized tgAAVCF for Cystic Fibrosis [abstract]. Journal of Cystic Fibrosis 2005;4 Suppl:S27. [CFGD Register: BD20b; CRS-ID: 5500100000002794]
8. Moss RB, Heald AE, 25E01 Study Group. A randomized phase 2B study of aerosolized tgAAVCF for treatment of cystic fibrosis [abstract]. American Thoracic Society International Conference; 2005 May 20-25; San Diego, USA. 2005:A179. [CFGD Register: BD20c]
9. Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Human Gene Therapy 2007;18(8):726-32. [CFGD Register: BD20d]
10. Moss RB, Milla C, Colombo J, Clancy JP, Zeitlin P, Spencer T, et al. A multicenter, double-blind, placebo-controlled, phase 2b study of aerosolized TGAAVCF for the treatment of cystic fibrosis [abstract]. Pediatric Pulmonology 2004;38(Suppl 27):257. [CFGD Register: BD20a]
11. Alton E. Single dose of PGM169/GL67A in CF patients. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=7094 Accessed on 22 September 2009. [UKCRN ID 7094]
12. Alton E, Davies JC, Davies G, Lees B, Mohamedhossen MH, Soussi S, et al. Safety evaluation of a single escalating dose of pGM169/GL67A in the nose and lung of individuals with cystic fibrosis. www.rbht.nhs.uk/research/projects/?entryid31=161410&catid=651&p=1 Accessed 22 September 2009. [Royal Brompton & Harefield NHS Trust Ref No.: 2007CF011B]
13. Davies JC, Davies G, Gill DR, Hyde SC, Boyd AC, Innes AJ, et al. Safety & expression of a single dose of lipid-mediated CFTR gene therapy to the upper & lower airways of patients with CF. Pediatric Pulmonology 2011;46(Suppl 34):Abstract 198.
14. Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, et al. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Human Gene Therapy 1996;7(9):1145-59. [CFGD Register: BD6; MEDLINE: 96369511]
15. Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 1997;4(3):199-209. [CFGD Register: BD4c; MEDLINE: 97281425]
16. Gill DR, Southern KW, Mofford KA, Sorgi F, Huang L, Higgins CF, et al. A Phase I clinical trial to assess the safety of DNA/liposome mediated gene transfer [abstract]. Tenth Annual North American Cystic Fibrosis Conference 1996;Suppl 13:264. [CFGD Register: BD4a; CRS-ID: 5500100000001372]
17. Hyde SC, Southern KW, Mofford KA, Sorgi F, Huang L, Higgins CF, et al. Towards DNA/liposome gene therapy for cystic fibrosis: A phase I clinical trial [abstract]. Pediatric Pulmonology 1996;22(Suppl 13):265. [CFGD Register: BD4b]
18. Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL, et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus see comments. Journal of Clinical Investigation 1999;104(9):1245-55. [CFGD Register: BD13]
19. Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 2000;7(13):1156-65. [CFGD Register: BD15b]
20. Southern KW, Hyde SC, Fitzjohn EM, Waddell BE, Egan JJ, Cole JY, et al. Repeated nasal administration of liposome-mediated CFTR gene transfer reagents; the clinical and immunological consequences [abstract]. Pediatric Pulmonology 1997;24(Suppl 14):265. [CFGD Register: BD15a]
21. Joseph PM, O'Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Human Gene Therapy 2001;12(11):1369-82. [CFGD Register: BD16]
22. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. New England Journal of Medicine 1995;333(13):823-31. [CFGD Register: BD1]
23. Noone PG, Hohneker KW, Gipson CA, Schwartzbach CJ, Efthimiou J, Johnson LG, et al. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1998;26(Suppl 17):260. [CFGD Register: BD10a]
24. Noone PG, Hohneker KW, Zhou Z, Johnson LG, Foy C, Gipson C, et al. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Molecular Therapy 2000;1(1):105-14. [CFGD Register: BD10b]
25. Porteous DJ, Dorin JR, McLachlan G, Davidson Smith H, Davidson H, Stevenson BJ, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 1997;4(3):210-8. [CFGD Register: BD5b; MEDLINE: 97281426]
26. Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, et al. DOTAP catonic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1996;22(Suppl 13):266. [CFGD Register: BD5a]
27. Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K, Desch JK, et al. Safety and biological efficacy of an adeno-associated virus vector - cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999;109(2 Pt 1):266-74. [CFGD Register: BD8b]
28. Wagner JA, Nepomuceno IB, Shah N, Messner AH, Moran ML, Norbash AM, et al. Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. Journal of Gene Medicine 1999;1(1):13-21. [CFGD Register: BD8c]
29. Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus [letter]. Lancet 1998;351(9117):1702-3. [CFGD Register: BD8a]
30. Wagner JA, Messner AH, Friborg S, Reynolds T, Guggino WB, Moss RB, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF in the maxillary sinus of CF patients [abstract]. Pediatric Pulmonology 1998;26(Suppl 17):260. [CFGD Register: BD9a]
31. Wagner JA, Messner AH, Moran ML, Guggino WB, Flotte TR, Wine JJ, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in CF patients with antrostomies [abstract]. Pediatric Pulmonology 1999;28(Suppl 19):223-4. [CFGD Register: BD9b]
32. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Human Gene Therapy 2002;13(11):1349-59. [CFGD Register: BD9c]
33. Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. Journal of Clinical Investigation 1996;97(6):1504-11. [CFGD Register: BD18]
34. Zabner J, Cheng SH, Meeker D, Launspach J, Balfour R, Perricone MA, et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. Journal of Clinical Investigation 1997;100(6):1529-37. [CFGD Register: BD7; MEDLINE: 97439775]
35. Zuckerman JB, Robinson CB, McCoy KS, Shell R, Sferra TJ, Chirmule N, et al. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Human Gene Therapy 1999;10(18):2973-85. [CFGD Register: BD14]
36. Clinical study protocol - a randomised, double-blind, placebo-controlled phase 2b clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Short title: repeated application of gene therapy in CF patients. Version: 3. Date 26.03.2012 [online]. http://www.eme.ac.uk/funded_projects/PDFs/111425protocol.pdf 2013. [CFGD Register: BD180d; CRS-ID: 5500100000011550]
37. Project brief: A randomised double-blind placebo controlled phase 2b clinical trial of repeated application of gene therapy in patients with cystic fibrosis [online]. http://www.eme.ac.uk/funded_projects/PDFs/111425info.pdf 2013. [CFGD Register: BD180c; CRS-ID: 5500100000011549]
38. Alton EW, Ashby D, Boyd C, Cheng S, Cunningham S, Davies JC, et al. Update on the UK CF gene therapy trial [abstract]. Pediatric Pulmonology 2012;47 Suppl 35:309, Abstract no: 245. [CFGD Register: BD180a; CRS-ID: 5500100000011542]
39. NCT01621867. A randomised, double-blind, placebo-controlled phase 2B clinical trial of repeated application of gene therapy in patients with cystic fibrosis. http://clinicaltrials.gov/show/NCT01621867 2013. [CFGD Register: BD180b; CRS-ID: 5500100000011548]
40. Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic Fibrosis: A worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Human Mutation 2002;19(6):575-606.
41. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. European Respiratory Journal 2004;23(1):146-58.
42. Conway SP, Pond MN, Bowler I, Smith DL, Simmonds EJ, Joanes DN, et al. The chest radiograph in cystic fibrosis: A new scoring system compared with the Chrispin-Norman and Brasfield scores. Thorax 1994;49:860-2.
43. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
44. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Advanced Drug Delivery Reviews 2002;54(11):1373-93.
45. FitzSimmons SC. The changing epidemiology of cystic fibrosis. Journal of Pediatrics 1993;122(1):1-9.
46. Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the Danish centre treated cystic fibrosis patients: Results of aggressive treatment. Pediatric Pulmonology 1996;21(3):153-8.
47. Griesenbach U, Geddes DM, Alton EW. Gene therapy for cystic fibrosis: an example for lung gene therapy. Gene Therapy 2004;11(Suppl 1):S43-50.
48. Griesenbach U, Boyd AC. Pre-clinical and clinical endpoint assays for cystic fibrosis gene therapy. Journal of Cystic Fibrosis 2005;4:89-100.
49. Griesenbach U. The UK gene therapy consortium research programme [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 3):S4.
50. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60.
51. Jüni P, Altman DG, Egger M. Systematic reviews in healthcare: Assessing the quality of controlled clinical trials. British Medical Journal 2001;323(7303):42-6.
52. Lee TW, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochemical Journal 2005;387(Pt 1):1-15.
53. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis W, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95(7):1005-15.
54. Ranganathan SC, Stocks J, Dezateux C, Bush A, Wade A, Carr S, et al. The evolution of airway function in early childhood following clinical diagnosis of cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2004;169(8):928-33.
55. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245(4922):1066-73.
56. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Annals of Human Genetics 2003;67(Pt 5):471-85.
57. Southern KW. Gene therapy for cystic fibrosis: current issues. British Journal of Hospital Medicine 1996;55(8):495-9.
58. Southern KW, Smyth RL. Design of clinical trials in cystic fibrosis. Lancet 2003;360:978-84.
59. Lee TWR, Southern KW. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD005599.pub2]
60. Lee TWR, Southern KW. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD005599.pub3]